172 related articles for article (PubMed ID: 35978207)
1. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer.
Harada T; Tsuji T; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujiwara H; Fujita T
Ann Surg Oncol; 2022 Dec; 29(13):8131-8139. PubMed ID: 35978207
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Postoperative Loss of Skeletal Muscle Mass in Patients Aged 70 Years or Older with Esophageal Cancer.
Harada T; Tatematsu N; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Tsuji T; Fujiwara H; Fujita T
Ann Surg Oncol; 2022 Sep; 29(9):5638-5645. PubMed ID: 35499789
[TBL] [Abstract][Full Text] [Related]
3. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
[TBL] [Abstract][Full Text] [Related]
4. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
5. Impact of early postoperative factors on changes in skeletal muscle mass after esophagectomy in older patients with esophageal cancer.
Harada T; Tatematsu N; Ueno J; Koishihara Y; Konishi N; Fukushima T; Fujiwara H; Fujita T; Hijikata N; Wada A; Ishikawa A; Tsuji T
Eur Geriatr Med; 2023 Feb; 14(1):203-210. PubMed ID: 36586085
[TBL] [Abstract][Full Text] [Related]
6. Association of sarcopenia with relative dose intensity of neoadjuvant chemotherapy in older patients with locally advanced esophageal cancer: A retrospective cohort study.
Harada T; Tsuji T; Ueno J; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujita T
J Geriatr Oncol; 2023 Sep; 14(7):101580. PubMed ID: 37478514
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapy.
Jang JY; Oh D; Noh JM; Sun JM; Kim HK; Shim YM
J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1167-1176. PubMed ID: 38613258
[TBL] [Abstract][Full Text] [Related]
8. Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer.
Nakashima Y; Saeki H; Hu Q; Tsuda Y; Zaitsu Y; Hisamatsu Y; Ando K; Kimura Y; Oki E; Mori M
Ann Surg Oncol; 2020 Feb; 27(2):492-498. PubMed ID: 31549319
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of skeletal muscle measurement by computed tomography in patients with esophageal cancer: changes in skeletal muscle mass due to neoadjuvant therapy and the effect on the prognosis.
Yamamoto M; Ozawa S; Koyanagi K; Kazuno A; Ninomiya Y; Yatabe K; Higuchi T; Kanamori K; Tajima K
Surg Today; 2023 Jun; 53(6):692-701. PubMed ID: 36763134
[TBL] [Abstract][Full Text] [Related]
10. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
[TBL] [Abstract][Full Text] [Related]
11. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
[TBL] [Abstract][Full Text] [Related]
12. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002.
Sato R; Tokunaga M; Mizusawa J; Sato Y; Ito S; Takahari D; Sano T; Onaya H; Yoshikawa T; Boku N; Terashima M
World J Surg; 2024 Jan; 48(1):163-174. PubMed ID: 38686798
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
Lyon TD; Frank I; Takahashi N; Boorjian SA; Moynagh MR; Shah PH; Tarrell RF; Cheville JC; Viers BR; Tollefson MK
Clin Genitourin Cancer; 2019 Jun; 17(3):216-222.e5. PubMed ID: 31060857
[TBL] [Abstract][Full Text] [Related]
16. Protocol of a pilot randomized clinical trial to evaluate nutritional support and rehabilitation on prevention of skeletal muscle mass loss during neoadjuvant chemotherapy in patients with esophageal cancer.
Miki Y; Nishi S; Tamura T; Imai T; Nambara M; Fukuoka T; Yoshii M; Toyokawa T; Lee S; Fujii H; Yoshida H; Ikebuchi M; Maeda K
PLoS One; 2024; 19(4):e0302003. PubMed ID: 38635741
[TBL] [Abstract][Full Text] [Related]
17. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
Amitani M; Oba T; Kiyosawa N; Morikawa H; Chino T; Soma A; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Maeno K; Ito KI
BMC Cancer; 2022 Mar; 22(1):327. PubMed ID: 35346102
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer.
Takahashi K; Watanabe M; Kozuki R; Toihata T; Okamura A; Imamura Y; Mine S; Ishizuka N
Ann Surg Oncol; 2019 Oct; 26(11):3727-3735. PubMed ID: 31313039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
